Loading…

Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey

Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model. We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart di...

Full description

Saved in:
Bibliographic Details
Published in:Anatolian journal of cardiology 2019-06, Vol.21 (6), p.322-330
Main Authors: Yaylalı, Yalın Tolga, Başarıcı, Ibrahim, Kılıçkıran Avcı, Burçak, Meriç, Murat, Sinan, Ümit Yaşar, Şenol, Hande, Küçükoğlu, Mehmet Serdar, Öngen, Zeki
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 330
container_issue 6
container_start_page 322
container_title Anatolian journal of cardiology
container_volume 21
creator Yaylalı, Yalın Tolga
Başarıcı, Ibrahim
Kılıçkıran Avcı, Burçak
Meriç, Murat
Sinan, Ümit Yaşar
Şenol, Hande
Küçükoğlu, Mehmet Serdar
Öngen, Zeki
description Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model. We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients. A total of 189 subjects (46+-17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up. The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication.
doi_str_mv 10.14744/AnatolJCardiol.2019.53498
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6683229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2257691041</sourcerecordid><originalsourceid>FETCH-LOGICAL-p294t-7e7e61ba6bd2a6ef1b99671ddf88165478f5fe1dbc438b38e8444cee8753ecf73</originalsourceid><addsrcrecordid>eNpdkU9P3DAQxS0EAkT5CpVFL73skrEd2-FQCa0ofwRCQvQcOcmka3Ds1E6W7revq1LUcprRvN88vdEQcgLFEoQS4vTcmym4m5WJnQ1uyQqoliUXld4hhwxEtWBMwe5bL_kBOU7pqSgKUFwDyH1ywAEEUwwOSf9g0zM1KWFKA_qJGt_RNMeN3RhHQ09HM9k8T_TFTms6zm4I3sQtXW9HjBP6ZIM_o3ezm2ybOYwUf2Yl77RIraePc3zG7Qey1xuX8Pi1HpFvXy8eV1eL2_vL69X57WJklZgWChVKaIxsOmYk9tBUlVTQdb3WIEuhdF_2CF3TCq4brlELIVpErUqOba_4Efnyx3ecmwG734micfUY7ZBD18HY-n_F23X9PWxqKTVnrMoGn18NYvgxY5rqwaYWnTMew5xqxjjLb-CszOind-hTmKPP52WqVLKCQkCmPv6b6C3K3xfwXxlgkPU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2257691041</pqid></control><display><type>article</type><title>Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey</title><source>PubMed (Medline)</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Yaylalı, Yalın Tolga ; Başarıcı, Ibrahim ; Kılıçkıran Avcı, Burçak ; Meriç, Murat ; Sinan, Ümit Yaşar ; Şenol, Hande ; Küçükoğlu, Mehmet Serdar ; Öngen, Zeki</creator><creatorcontrib>Yaylalı, Yalın Tolga ; Başarıcı, Ibrahim ; Kılıçkıran Avcı, Burçak ; Meriç, Murat ; Sinan, Ümit Yaşar ; Şenol, Hande ; Küçükoğlu, Mehmet Serdar ; Öngen, Zeki</creatorcontrib><description>Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model. We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients. A total of 189 subjects (46+-17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up. The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication.</description><identifier>ISSN: 2149-2263</identifier><identifier>EISSN: 2149-2271</identifier><identifier>DOI: 10.14744/AnatolJCardiol.2019.53498</identifier><identifier>PMID: 31142721</identifier><language>eng</language><publisher>Turkey: Kare Publishing</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cardiology ; Cardiovascular disease ; Chronic Disease ; Cohort Studies ; Congenital diseases ; Connective Tissue Diseases - complications ; Echocardiography ; Female ; Follow-Up Studies ; Heart ; Heart Defects, Congenital - complications ; Humans ; Hypertension, Pulmonary - diagnostic imaging ; Hypertension, Pulmonary - etiology ; Hypertension, Pulmonary - mortality ; Male ; Medicine ; Middle Aged ; Mortality ; Original Investigation ; Pulmonary Embolism - complications ; Pulmonary hypertension ; Risk Assessment ; Survival Rate ; Thromboembolism ; Turkey ; Young Adult</subject><ispartof>Anatolian journal of cardiology, 2019-06, Vol.21 (6), p.322-330</ispartof><rights>2019. Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the associated terms available at http://www.anakarder.com/Copyright</rights><rights>Copyright: © 2019 Turkish Society of Cardiology 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2257691041/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2257691041?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31142721$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yaylalı, Yalın Tolga</creatorcontrib><creatorcontrib>Başarıcı, Ibrahim</creatorcontrib><creatorcontrib>Kılıçkıran Avcı, Burçak</creatorcontrib><creatorcontrib>Meriç, Murat</creatorcontrib><creatorcontrib>Sinan, Ümit Yaşar</creatorcontrib><creatorcontrib>Şenol, Hande</creatorcontrib><creatorcontrib>Küçükoğlu, Mehmet Serdar</creatorcontrib><creatorcontrib>Öngen, Zeki</creatorcontrib><title>Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey</title><title>Anatolian journal of cardiology</title><addtitle>Anatol J Cardiol</addtitle><description>Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model. We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients. A total of 189 subjects (46+-17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up. The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Chronic Disease</subject><subject>Cohort Studies</subject><subject>Congenital diseases</subject><subject>Connective Tissue Diseases - complications</subject><subject>Echocardiography</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Heart Defects, Congenital - complications</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - diagnostic imaging</subject><subject>Hypertension, Pulmonary - etiology</subject><subject>Hypertension, Pulmonary - mortality</subject><subject>Male</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Original Investigation</subject><subject>Pulmonary Embolism - complications</subject><subject>Pulmonary hypertension</subject><subject>Risk Assessment</subject><subject>Survival Rate</subject><subject>Thromboembolism</subject><subject>Turkey</subject><subject>Young Adult</subject><issn>2149-2263</issn><issn>2149-2271</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkU9P3DAQxS0EAkT5CpVFL73skrEd2-FQCa0ofwRCQvQcOcmka3Ds1E6W7revq1LUcprRvN88vdEQcgLFEoQS4vTcmym4m5WJnQ1uyQqoliUXld4hhwxEtWBMwe5bL_kBOU7pqSgKUFwDyH1ywAEEUwwOSf9g0zM1KWFKA_qJGt_RNMeN3RhHQ09HM9k8T_TFTms6zm4I3sQtXW9HjBP6ZIM_o3ezm2ybOYwUf2Yl77RIraePc3zG7Qey1xuX8Pi1HpFvXy8eV1eL2_vL69X57WJklZgWChVKaIxsOmYk9tBUlVTQdb3WIEuhdF_2CF3TCq4brlELIVpErUqOba_4Efnyx3ecmwG734micfUY7ZBD18HY-n_F23X9PWxqKTVnrMoGn18NYvgxY5rqwaYWnTMew5xqxjjLb-CszOind-hTmKPP52WqVLKCQkCmPv6b6C3K3xfwXxlgkPU</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Yaylalı, Yalın Tolga</creator><creator>Başarıcı, Ibrahim</creator><creator>Kılıçkıran Avcı, Burçak</creator><creator>Meriç, Murat</creator><creator>Sinan, Ümit Yaşar</creator><creator>Şenol, Hande</creator><creator>Küçükoğlu, Mehmet Serdar</creator><creator>Öngen, Zeki</creator><general>Kare Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190601</creationdate><title>Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey</title><author>Yaylalı, Yalın Tolga ; Başarıcı, Ibrahim ; Kılıçkıran Avcı, Burçak ; Meriç, Murat ; Sinan, Ümit Yaşar ; Şenol, Hande ; Küçükoğlu, Mehmet Serdar ; Öngen, Zeki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p294t-7e7e61ba6bd2a6ef1b99671ddf88165478f5fe1dbc438b38e8444cee8753ecf73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Chronic Disease</topic><topic>Cohort Studies</topic><topic>Congenital diseases</topic><topic>Connective Tissue Diseases - complications</topic><topic>Echocardiography</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Heart Defects, Congenital - complications</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - diagnostic imaging</topic><topic>Hypertension, Pulmonary - etiology</topic><topic>Hypertension, Pulmonary - mortality</topic><topic>Male</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Original Investigation</topic><topic>Pulmonary Embolism - complications</topic><topic>Pulmonary hypertension</topic><topic>Risk Assessment</topic><topic>Survival Rate</topic><topic>Thromboembolism</topic><topic>Turkey</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yaylalı, Yalın Tolga</creatorcontrib><creatorcontrib>Başarıcı, Ibrahim</creatorcontrib><creatorcontrib>Kılıçkıran Avcı, Burçak</creatorcontrib><creatorcontrib>Meriç, Murat</creatorcontrib><creatorcontrib>Sinan, Ümit Yaşar</creatorcontrib><creatorcontrib>Şenol, Hande</creatorcontrib><creatorcontrib>Küçükoğlu, Mehmet Serdar</creatorcontrib><creatorcontrib>Öngen, Zeki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Anatolian journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yaylalı, Yalın Tolga</au><au>Başarıcı, Ibrahim</au><au>Kılıçkıran Avcı, Burçak</au><au>Meriç, Murat</au><au>Sinan, Ümit Yaşar</au><au>Şenol, Hande</au><au>Küçükoğlu, Mehmet Serdar</au><au>Öngen, Zeki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey</atitle><jtitle>Anatolian journal of cardiology</jtitle><addtitle>Anatol J Cardiol</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>21</volume><issue>6</issue><spage>322</spage><epage>330</epage><pages>322-330</pages><issn>2149-2263</issn><eissn>2149-2271</eissn><abstract>Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model. We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients. A total of 189 subjects (46+-17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up. The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication.</abstract><cop>Turkey</cop><pub>Kare Publishing</pub><pmid>31142721</pmid><doi>10.14744/AnatolJCardiol.2019.53498</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2149-2263
ispartof Anatolian journal of cardiology, 2019-06, Vol.21 (6), p.322-330
issn 2149-2263
2149-2271
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6683229
source PubMed (Medline); Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Adolescent
Adult
Aged
Aged, 80 and over
Cardiology
Cardiovascular disease
Chronic Disease
Cohort Studies
Congenital diseases
Connective Tissue Diseases - complications
Echocardiography
Female
Follow-Up Studies
Heart
Heart Defects, Congenital - complications
Humans
Hypertension, Pulmonary - diagnostic imaging
Hypertension, Pulmonary - etiology
Hypertension, Pulmonary - mortality
Male
Medicine
Middle Aged
Mortality
Original Investigation
Pulmonary Embolism - complications
Pulmonary hypertension
Risk Assessment
Survival Rate
Thromboembolism
Turkey
Young Adult
title Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A20%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20assessment%20and%20survival%20of%20patients%20with%20pulmonary%20hypertension:%20Multicenter%20experience%20in%20Turkey&rft.jtitle=Anatolian%20journal%20of%20cardiology&rft.au=Yaylal%C4%B1,%20Yal%C4%B1n%20Tolga&rft.date=2019-06-01&rft.volume=21&rft.issue=6&rft.spage=322&rft.epage=330&rft.pages=322-330&rft.issn=2149-2263&rft.eissn=2149-2271&rft_id=info:doi/10.14744/AnatolJCardiol.2019.53498&rft_dat=%3Cproquest_pubme%3E2257691041%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p294t-7e7e61ba6bd2a6ef1b99671ddf88165478f5fe1dbc438b38e8444cee8753ecf73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2257691041&rft_id=info:pmid/31142721&rfr_iscdi=true